NHS cancer patients denied life-saving drugs due to Brexit costs, report finds

British cancer patients are being denied life-saving drugs and trials of revolutionary treatments are being derailed by the red tape and extra costs brought on by Brexit, a leaked report warns.

Soaring numbers are being diagnosed with the disease amid a growing and ageing population, improved diagnosis initiatives and wider public awareness – making global collaborations to find new medicines essential.

But five years after the UK’s exit from the EU, the most comprehensive analysis of its kind concludes that while patients across Europe are benefiting from a golden age of pioneering research and novel treatments, Britons with cancer have “lost out” thanks to rising prices and red tape.

Brexit has “damaged the practical ability” of doctors to offer NHS patients life-saving new drugs via international clinical trials, according to the 54-page report obtained by the Guardian.

In some cases, the cost of importing new cancer drugs for Britons has nearly quadrupled as a result of post-Brexit red tape. Some trials have had shipping costs alone increase to 10 times since Brexit.

The extra rules and costs have had a “significant negative impact” on UK cancer research, creating “new barriers” that are “holding back life-saving research” for Britons, the report says.

In some cases, the impact has been devastating. Children are among the NHS cancer patients whose tumours have returned or treatment has stopped working, leaving them in limbo and denied drugs that could extend or save their lives, senior doctors told the Guardian.

Read full story

Source: The Guardian, 20 April 2025